Loading
Life sciences · Journal article
Power System Technology · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Cancer outcomes depend heavily on how early a tumor is found, how accurately it is characterized, and how quickly change sin its behavior arerecognized during therapy. Medical imaging is the principal source of this information, yet the volume and complexity of imaging data now exceed what human readers can interpret consistently. Artificial intelligence (AI), especially deep learning and radiomics, offers a way to extract quantitative, reproducible information from images and to convert it into predictions that support clinical decisions. This article reviews the evidence for AI across four stages of the oncology pathway:earlydetection, classification, treatment response assessment, and disease progression monitoring. It then develops a compact mathematical framework for each stage, covering convolutional detection models, receiver operating characteristic (ROC) analysis, Bayesian interpretation of screening results, tumor growth and treatment response kinetics, and survival modeling with a Cox proportional hazards formulation. Worked calculations show that (a) a classifier with 94% sensitivity and 92% specificity has a positive predictive value of only 10.6% at 1% prevalence,(b) detecting a lesion at 0.5 cm rather than 1.0 cm gives three tumor doublings of lead time,(c) a 30% decrease in diameter underRECIST1.1 corresponds to a 65.7% decrease in volume, and (d) a high-risk imaging signature with a hazard ratio of 2.5 shortens median progression-free survival from 34.7 to 13.9 months in the illustrative model. Five graphs and three tables summarize the results. The model outputs are illustrative simulations built from stated assumptions and are not patient data. The article closes with a discussion of validation, bias, explainability, and implementation barriers.